how many people are on glp-1 drugs Just Americans taking GLP-1s now Poll: 1 in 8 Adults

Harno E, Cottrell EC, Yu A et al (2013) 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors still improve metabolic phenotype in male 11beta-HSD1 knockout mice suggesting off-target mechanisms

This analysis concludes that while GLP-1 agonists demonstrate significant promise, their ultimate impact depends on addressing cost, accessibility, and long-term sustainability concerns

This is where GLP-1 mimetics can be helpful, particularly when used as a bridge to more sustainable diet and lifestyle habits

The semaglutide versus tirzepatide comparison is detailed and nuanced, with differences in side effect profiles, dosing convenience, and insurance coverage all playing a role

doi: 10.1111/dom.13135

At the same time, the arrival of generic liraglutide and evolving insurance coverage are reshaping access and affordability